Zobrazeno 1 - 10
of 166
pro vyhledávání: ''
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
Publikováno v:
Lung Cancer. 143:40-46
Objectives Little is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS. Materials and methods Thirty-seven consecutive patients with advanced LCNEC were selected from the Da
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Laila J. Tata, Andrew Wilcock, Richard Hubbard, Paul Beckett, Vanessa Beattie, Yvonne Nartey, Aamir Khakwani, Ian Woolhouse, Iain A. Stewart
Publikováno v:
Lung Cancer. 140:27-34
Objectives Healthcare systems increasingly recognise the importance of service users’ perspectives for improving care organisation and delivery. The English Cancer Patient Experience Survey (CPES) is carried out annually, however, its representativ
Autor:
Bryan J. Ager, J.D. Gruhl, Stacey Wells, Randa Tao, Kristine E. Kokeny, Ying J. Hitchcock, Gregory J. Stoddard
Publikováno v:
Lung Cancer
OBJECTIVES: To compare patterns of care and overall survival (OS) between stereotactic body radiotherapy (SBRT) and percutaneous local tumor ablation (LTA) for non-surgically managed early-stage non-small-cell lung cancer (NSCLC). MATERIALS AND METHO
Autor:
Youngjoo Lee, Nak Jung Kwon, Sung-Ho Goh, Jae Hyun Jeon, Jin Ho Choi, Moon Soo Kim, Hanseong Roh, Geon Kook Lee, Hee Chul Yang, Ji Young Yun, Ji Youn Han, Jong Mog Lee
Publikováno v:
Lung Cancer. 136:15-22
Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown.We screened 3,241 lung
Autor:
David Fenton, Ashley T. Freeman, Zia Poonja, Elaine S. Wai, G. Geller, Doran Ksienski, E. Brooks, Sarah Irons, Mary Lesperance, Nicole S. Croteau, Angela Chan, Leathia Fiorino
Publikováno v:
Lung Cancer. 133:110-116
While pembrolizumab improves overall survival (OS) in a subset of advanced nonsmall cell lung cancer (aNSCLC) patients (pts) in clinical trials, individuals with poor Eastern Cooperative Oncology Group performance status (ECOG PS) were excluded. Furt
Autor:
Ying Zheng, Yonggen Jiang, Haiquan Chen, Fei Liang, Chen Fu, Meiying Zhu, Chunxiao Wu, Haiyan Gu, Zeliang Xuan
Publikováno v:
Lung Cancer. 132:114-118
LDCT screening for lung cancer has been widely used in China since the release of the NLST trial data in 2011, but little is known about its impact on the incidence and mortality rates of lung cancer in China.Official cancer registry data of lung can
Autor:
David J. Sher, Chad G. Rusthoven, Lawrence Eric Feldman, Michael T. Spiotto, Mary Pasquinelli, Corey C. Foster, Matthew Koshy
Publikováno v:
Lung Cancer. 130:162-168
Objectives Adjuvant chemotherapy is routinely offered post-surgical resection for early stage non-small-cell lung cancer (NSCLC) ≥4 cm; however, its role following definitive stereotactic body radiotherapy (SBRT) has not been well defined. We inves
Autor:
Ian Campbell, Robin Ghosal, Keir Lewis, Gareth Davies, LungCast Investigators, Gareth Collier, Kathryn Davies, Rachel Gemine, Diane Parry
Publikováno v:
Lung Cancer. 129:1-7
To update the prevalence of smoking in people as they were diagnosed with non-small cell lung cancer (NSCLC) and to see whether smoking status at baseline and quitting are independently associated with 1-year survival.A real-world cohort study follow
Autor:
Hironori Haga, Makoto Sonobe, Akihiro Ohsumi, Terumasa Sowa, Toyofumi F. Chen-Yoshikawa, Yojiro Yutaka, Akihiko Yoshizawa, Shinya Neri, Hiroshi Date, Masatsugu Hamaji, Toshi Menju, Toshihiko Sato, Daisuke Nakajima
Publikováno v:
Lung Cancer. 128:13-19
Microscopic vessel invasion (MVI) and visceral pleural invasion (VPI) have been recently reported as poor prognostic factors of non-small cell lung cancer. Epithelial-mesenchymal transition (EMT) and cancer stemness (CS) are known malignant phenotype